Why the study?
Does gemfibrozil reduce cardiovascular events in men with coronary heart disease, low HDL-C, and diabetes or hyperinsulinemia?
Population
2,531 men with coronary heart disease, a high-density lipoprotein cholesterol level of 40 mg/dL or less, and…
Comparison
Gemfibrozil 1200 mg/d vs Matching placebo
Design
RCT, randomized, placebo-controlled
Follow-up
average 5.1 years
Loading...
Supports gemfibrozil consideration in men with CHD, low HDL-C, diabetes or hyperinsulinemia; extends RCT evidence to these insulin-resistant subgroups.
Does gemfibrozil reduce cardiovascular events in men with coronary heart disease, low HDL-C, and diabetes or hyperinsulinemia?
Gemfibrozil significantly reduces major cardiovascular events in men with coronary heart disease and low HDL-C who also have diabetes or hyperinsulinemia.
A 2002 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: